Patients must have undergone complete surgical resection of their stage IB (>=  cm), II, or non-squamous IIIA NSCLC per American Joint Committee on Cancer (AJCC) th edition and have had negative margins; N disease is not allowed
All of the following staging criteria (according to the th edition of the American Joint Committee on Cancer [AJCC] Cancer Staging Manual) must be met:\r\n* By pathologic evaluation, primary tumor must be pT-\r\n* By pathologic evaluation, ipsilateral nodes must be pN, pN (pNmi, pNa, pNb, pNc), pNa, pNb, pNa, or pNb\r\n* If pN, pathological tumor must be >= . cm
Clinical stage T- N M breast cancer at diagnosis (prior to the start of neoadjuvant chemotherapy) by American Joint Committee on Cancer (AJCC) staging th edition
Patients must have undergone complete surgical resection of their stage IB (>=  cm), II or IIIA NSCLC according to the American Joint Committee on Cancer (AJCC) th edition and have had negative surgical margins
Stage IV disease (includes Ma, Mb, or recurrent disease), according to the th edition of the lung cancer tumor, node, and metastasis (TNM) classification system
Histologically or cytologically confirmed, resectable Stage II, IIIA, or Select IIIB (TN only) NSCLC of squamous or non-squamous histology. Staging should be based on the th edition of the AJCC/UICC staging system
Cytologically or histologically confirmed diagnosis of Stage IV NSCLC as defined by the American Joint Committee on Cancer Staging Criteria for Lung Cancer (AJCC th edition ).
Participants must have histologically confirmed stage IIIA or IIIB non-squamous non-small cell lung cancer (NSCLC) (American Joint Committee on Cancer [AJCC] th edition); patients with a clinical stage of IIIB are allowed only if they are thought to be a candidate for concurrent chemoradiation
Participants must have histologically confirmed stage IV non-small cell lung cancer (NSCLC) (per American Joint Committee on Cancer [AJCC] th edition) from time of diagnosis with either the LR or exon  deletion activating EGFR mutation as identified in a Clinical Laboratory Improvement Act [CLIA]-approved laboratory
Participants must have histologically confirmed stage IV NSCLC (per American Joint Committee on Cancer [AJCC] th edition) from time of diagnosis with either the LR or exon  deletion activating EGFR mutation as identified in a Clinical Laboratory Improvement Act (CLIA)-approved laboratory
Patients with non-metastatic breast cancer are eligible; this includes American Joint Committee on Cancer (AJCC) th edition left- or right-sided breast cancer clinical or pathologic stage I, II, III or loco-regionally recurrent at time of diagnosis; for patients that receive neoadjuvant chemotherapy, AJCC th edition left- or right-sided breast cancer pathologic stage yp , I, II, III are eligible
American Joint Committee on Cancer (AJCC) th edition clinical stages Tc to Tc
Histologically or cytologically-confirmed recurrent or resistant (progression within  months following the last administered platinum based therapy or progression after subsequent therapy in previously relapsed subjects), stage III-IV epithelial ovarian, fallopian tube or peritoneal cancer subjects (according to American Joint Committee on Cancer/Union for International Cancer Control TNM and International Federation of Gynecology and Obstetrics Staging System, th edition) whose disease has progressed following adjuvant therapy or therapy for metastatic disease.
Has a histologically or cytologically confirmed diagnosis of stage IV (Ma or Mb-American Joint Committee on Cancer [AJCC] th edition) squamous NSCLC.
Pathologically proven (either histologic or cytologic) diagnosis of stage IIB-IIIB non-small cell lung cancer (NSCLC); according to American Joint Committee on Cancer (AJCC) staging, th edition\r\n* Staging workup must include: brain imaging (CT head or magnetic resonance imaging [MRI] brain) and PET/CT\r\n* Pleural effusions must have cytology to rule out malignant involvement unless too small to undergo thoracentesis per radiology
Patients must have stage III, IVa or IVb disease as determined by imaging studies and complete head and neck exam; staging evaluation should be in accordance with the American Joint Committee on Cancer Staging Manual, th edition
Pathologically proven (either histologic or cytologic) diagnosis of NSCLC with any of the following stages (according to the American Joint Committee on Cancer [AJCC] Staging Manual, th edition):\r\n* Stage IIIA or IIIB\r\n* Stage II NSCLC with medical contraindication to curative surgical resection\r\n* Stage IV disease with solitary brain metastasis that has been treated radically (eg: with surgical resection or stereotactic radiosurgery) and thoracic disease that would be classified as stage II-III
Pathologically proven (either histologic or cytologic) diagnosis of stage IIIA or IIIB non-small cell lung cancer; (according to American Joint Committee on Cancer [AJCC] staging, th edition) within  weeks of registration; the patient should have histologically or cytologically confirmed N disease
AJCC (American Joint Committee on Cancer) th Ed. clinical stage II-III.
Must meet stage II - III group criteria per AJCC Staging manual th edition.
Phase I and expansion cohort: Patients must have histologically or cytologically confirmed adenocarcinoma of the breast associated with clinical stage: IV (see American Joint Committee on Cancer [AJCC] staging criteria, th edition) or stage IIB-IIIC (expansion cohort only)
Pathologic stages T-Tb, N-Nx-N, M- as staged by the pathology report (American Joint Committee on Cancer [AJCC] criteria th edition [Ed.])
Subjects must have cytologically or histologically-confirmed unresectable melanoma that harbors a BRAF V mutation determined by pyrosequencing assay or equivalent genotyping assay in a Clinical Laboratory Improvement Act (CLIA) certified laboratory, meeting one of the following American Joint Committee on Cancer (AJCC) (th edition) staging criteria:\r\n* AJCC stage IV (Tany, Nany, Ma(), Mb(), Mc() or Md())\r\n* AJCC stage IIIC (at least Nb) or IIID with unresectable nodal/locoregional involvement
Patients must have a clinical T stage documented by the treating urologist/medical oncologist within  days prior to treatment start using the seventh (th) edition American Joint Committee on Cancer (AJCC) staging system, recorded as the urologists/medical oncologists best clinical assessment of extent of local disease by digital rectal examination and available imaging studies such as transrectal ultrasound, computed tomography (CT) scan, and/or MRI
Stage IV (according to the American Joint Committee on Cancer [AJCC] th edition).
Clinical stage T-Tc, any N, M primary tumor by American Joint Committee on Cancer (AJCC) th edition clinical staging
Patients who have stage III-IV disease without distant metastases (M) of ) oral cavity, ) larynx, ) hypopharynx ) oropharynx (human papillomavirus [HPV] negative [neg]) using American Joint Committee on Cancer (AJCC) th edition
Patients who have oropharyngeal cancer that is HPV positive, stage II-III disease without distant metastases (M) using AJCC th edition
Unicentric American Joint Committee on Cancer (AJCC) th edition TNM tumor measuring no greater than . cm in longest dimension on initial imaging with either breast magnetic resonance imaging (MRI) and/or mammogram
Histologically or cytologically confirmed nasopharyngeal carcinoma, stage II-IV by American Joint Committee on Cancer (AJCC) th edition, endemic-type (defined as World Health Organization [WHO] type a and b non-keratinizing or undifferentiated subtypes, excluding WHO type I keratinizing subtype) performed on a biopsy that occurred within  days of registration
Clinical stage T-, N-, or small volume Nb (American Joint Committee on Cancer [AJCC], th ed.), with no distant metastases, based on routine staging workup.
Clinical stage T-T, N-Nb or T, N-Nb (American Joint Committee on Cancer [AJCC] th edition) with no distant metastases based on the following diagnostic workup
Clinical stage Tc-Tc, any N, M primary tumor by American Joint Committee on Cancer (AJCC) th edition clinical staging prior to neoadjuvant chemotherapy
Clinical stage I (breast tumor >= . cm in diameter), stage II or stage III breast cancer (according to the American Joint Committee on Cancer [AJCC] Staging Manual, th Edition, ); multifocal disease is allowed if confined to  breast, as long as one tumor is at least  cm and meets all of the other inclusion criteria
Patients with American Joint Committee on Cancer (AJCC) (th edition, ) N-N nodal disease or T-T primary tumor
Patient must have pathologically-confirmed and previously untreated:\r\n* Non-small cell lung cancer, stage IIIA (T- N M) OR\r\n* Localized esophageal cancer, >= T, or N+, and M according to the American Joint Committee on Cancer (AJCC) th edition staging
Stage IA-IIIA NSCLC by th edition American Joint Committee on Cancer (AJCC) staging (that is deemed to be surgically resectable by a board certified thoracic surgeon
Stage IIIB or IV NSCLC as per th edition AJCC staging
All subjects must be either recurrent or stage IV American Joint Committee on Cancer (AJCC) (th edition) and have histologically confirmed Merkel cell carcinoma with confirmed pathology in order to be eligible
Clinical stage I-IVB (American Joint Committee on Cancer [AJCC], th edition); stages I-II glottic cancer are excluded
Clinical or pathologic stage Stage III-IVb per the American Joint Committee on Cancer (AJCC), th edition.
Stage I or II; TN and TN stage III presentations per AJCC th edition
Have pathologically confirmed diagnosis of advanced NSCLC (stage IIIB or stage IV, as defined by the American Joint Committee on Cancer staging system-TNM th edition, )
Patients must have histologically or cytologically confirmed stage IIIB or IV (American Joint Committee on Cancer, th edition; AJCC ) non-small cell lung cancer
Patient's disease state must be American Joint Committee on Cancer (AJCC) th edition stage I-III
Histologically or cytologically proven diagnosis of NSCLC that is locally advanced (stage IIIB) unsuitable for radiotherapy or metastatic (stage IV) according to the th edition of tumor, node, metastasis (TNM) in Lung Cancer published by the International Union Against Cancer and the American Joint Committee on Cancer.
Stage IIIB-IV, locally advanced or metastatic disease according to the  th edition of the AJCC lung cancer TNM classification system
Patients must have FDG-avid and pathologically proven Stage IIA-IIIB non-small cell lung cancer (NSCLC) (according to American Joint Committee on Cancer [AJCC] staging, th edition)
Clinical stage =< Tb (American Joint Committee on Cancer [AJCC] th Edition Staging Manual) and no radiographic evidence of T or T disease
Clinical stage T-Tc, any N, M primary tumor by American Joint Committee on Cancer (AJCC) th edition clinical staging prior to neoadjuvant chemotherapy, with residual invasive breast cancer after neoadjuvant therapy; if the patient has invasive cancer in the contralateral breast, she is not eligible for this study
Clinical stage Tc-Tc, any N, M primary tumor by American Joint Committee on Cancer (AJCC) th edition clinical staging prior to neoadjuvant chemotherapy, with residual invasive breast cancer after neoadjuvant therapy; if the patient has invasive cancer in the contralateral breast, she is not eligible for this study
Clinical American Joint Committee on Cancer (AJCC) th edition stage TNM, TNM or TNM based on physical examination, CT scan chest/abdomen/pelvis, and pelvic magnetic resonance imaging (MRI) or endorectal ultrasound
Documented history of clinical stage IV (any T, any N, Ma/b) disease as per American Joint Committee on Cancer (AJCC) staging system th edition
Patients must be classified post-operatively as Stage IB (? cm in the longest diameter), II or IIIA on the basis of pathologic criteria. Note: Although TNM tumours have been reclassified to stage IIIB in the th edition of the IASLC staging system, these patients remain eligible (as stage IIIA under the th edition criteria).
Clinical American Joint Committee on Cancer (AJCC) stage (th edition) IIA-IIIB NSCLC (T-N-M)
Patients with American Joint Committee on Cancer (AJCC) th edition clinical stage IIB-IIIC
Clinical stage a =< T-a (American Joint Committee on Cancer [AJCC] th edition)
Pathologically proven (either histologic or cytologic) diagnosis of stage IV or recurrent non-small cell lung cancer (according to American Joint Committee on Cancer [AJCC] staging, th edition)
Clinical stage T-b (American Joint Committee on Cancer [AJCC] th edition) and PSA <  ng/mL within  days prior to registration; PSA should not be obtained within  days after prostate biopsy
Histologically confirmed stage III colorectal cancer as determined by American Joint Committee on Cancer (AJCC) th edition
Patients must have documented, clinically measurable th edition American Joint Committee on Cancer (AJCC) stage IIIB/C (bulky nodal and/or in transit disease) or stage IV (distant metastatic) melanoma; patients with brain metastases that have been appropriately treated with surgical resection and/or radiation are eligible for inclusion if they meet the performance status and life expectancy criteria; patients who are BRAF VE mutation positive need to have failed, refused, or be ineligible for at least  lines of therapy (vemurafenib plus one other regimen)
Clinical stage Tb-Tb, N-Nx, M-Mx (American Joint Committee on Cancer [AJCC] th Edition)\r\n* T-stage and N-stage determined by physical exam and available imaging studies (ultrasound, computed tomography [CT], and/or magnetic resonance imaging [MRI])\r\n* M-stage determined by physical exam, CT or MRI; bone scan not required unless clinical findings suggest possible osseous metastases
Patients must have a histologically or cytologically confirmed, unresectable, advanced or metastatic (Stage IV per AJCC th edition TNM staging) NSCLC
Patient with histologically or cytologically confirmed non-resectable or metastatic stage  (non-resectable IIIB or IIIC, AJCC TNM staging system th edition) or stage  melanoma
Clinical stage II or stage III (by American Joint Committee on Cancer [AJCC] th edition) breast cancer eligible for neoadjuvant chemotherapy with complete surgical excision of the breast cancer after neoadjuvant therapy as the treatment goal
Stage IV disease or stage IIIC disease (using the th edition American Joint Committee on Cancer [AJCC] criteria) not amenable to local therapy
If both of the following conditions are present, the patient is ineligible:\r\n* <  pack-year smoking history\r\n* p-positive carcinoma of the oropharynx or unknown primary that are T-, N-b (AJCC th Edition)\r\n** Note: in the event that a registered patient has a p-positive result on central review with the tumor and nodal stage T-, N-b (AJCC th Edition), then the site will be notified that the patient is ineligible
Participants must have presented at initial diagnosis with extensive-stage disease (defined as stage IV [T any, N any, Ma/b] per National Comprehensive Cancer Network [NCCN] guidelines version ., American Joint committee on Cancer [AJCC] staging manual, seventh [th] edition, )
Histologically confirmed diagnosis of non-small cell lung cancer (NSCLC); patients should have stage IV disease (American Joint Committee on Cancer [AJCC] th edition), stage IIIb disease that is not amenable to potentially curative treatment (e.g. chemoradiotherapy) or unequivocal progression in a prior irradiated field; measurable or evaluable disease is required
Oropharyngeal primaries have to be human papillomavirus (HPV) p negative, unless by American Joint Committee on Cancer (AJCC) th edition staging they are cTa, cTb, cN and/or cN tumors
Clinical stages Tc-Tc (American Joint Committee on Cancer [AJCC] sixth edition)
Patients with stage IV (locally advanced or metastatic) disease; the American Joint Committee on Cancer (AJCC) cancer staging manual, th edition will be used for staging; Response Evaluation Criteria in Solid Tumors (RECIST) . criteria will be used for measurable disease
Patients must have histologically or cytologically confirmed:\r\n* Extensive stage small cell lung cancer (SCLC) or \r\n* Stage IV (Ma or Mb according to American Joint Committee on Cancer [AJCC] Staging Manual, th edition) large cell neuroendocrine non-small cell lung cancer (NSCLC) or \r\n* Small cell carcinoma of unknown primary or extrapulmonary origin and must be a candidate for systemic therapy \r\n** NOTE: The extensive disease SCLC classification for this protocol includes all patients with disease sites not defined as limited stage; limited stage disease category includes patients with disease restricted to one hemithorax with regional lymph node metastases, including hilar, ipsilateral and contralateral mediastinal, and/or ipsilateral supraclavicular nodes; extensive disease patients are defined as those patients with extrathoracic metastatic disease, malignant pleural effusion, bilateral or contralateral supraclavicular adenopathy
Patient must have histologically or cytologically confirmed oral cavity squamous cell carcinoma of stage , , a, or b (by American Joint Committee on Cancer [AJCC] th edition [ed.])
Pathologically proven diagnosis of stage IIIA (T-T) (American Joint Committee on Cancer [AJCC] Staging, th edition) with a single primary lung parenchymal lesion and ipsilateral positive mediastinal nodes within  weeks of registration; note: the primary tumor does not require tissue diagnosis; documentation of non-small cell carcinoma may originate from the mediastinal node biopsy or aspiration
Patients must have histologically or cytologically confirmed stage IV (American Joint Committee on Cancer [AJCC] th Edition) or recurrent non-small cell lung cancer (NSCLC)
Complete surgical resection, pathologic stage IA-B, IIA-B, IIIA-B by the American Joint Committee on Cancer (AJCC) th Edition staging criteria
Patients with synchronous disease at initial diagnosis must have metastatic (M) disease (American Joint Committee on Cancer [AJCC] th edition T-N-M)
Patients must have appropriate staging studies identifying them as American Joint Committee on Cancer (AJCC) stage II or III non small cell lung cancer, (according to AJCC staging, th edition), or recurrent non small cell lung cancer; histologic confirmation of cancer will be required by biopsy or cytology within  months of study entry
Stage IV locally advanced or metastatic urothelial carcinoma (according to American Joint Committee on Cancer th edition guidelines) with documented disease progression while on a PD- pathway targeted therapy.
Patients will be staged according to the th edition American Joint Committee on Cancer (AJCC) staging system with pathologic stage T-, N-, M- being eligible
Either clinical or pathological Stage I (Tc), II, or III according to AJCC th edition
Pathologically or cytologically confirmed NSCLC Stage IV Cancer (includes cytologically proven pleural effusion or pericardial effusion) or recurrent disease. Staging is based on American Joint Committee on Cancer (AJCC) Staging for NSCLC th edition (R-)
Histologically confirmed Stage III (unresectable) or Stage IV melanoma, per the American Joint Committee on Cancer (AJCC) Staging Manual (th edition)
There must be histologic confirmation of high risk, adenocarcinoma of the colon defined as AJCC th Edition Stage IIIB or IIIC.
Have stage IV disease at the time of study entry (American Joint Committee on Cancer [AJCC] Staging Manual, th edition).
Stage IB (with a primary tumor >= cm), IIA, IIB, or IIIA (according to American Joint Committee on Cancer [AJCC] th edition); patients with stage IIIA must not have more than one mediastinal lymph node station involved by tumor
Participant has stage IIIB or IV NSCLC (American Joint Committee on Cancer [AJCC] Staging Manual, th edition [Edge, ]) and was pretreated with only  prior systemic platinum based chemotherapy.
Stage II or III esophageal carcinoma according to the American Joint Committee on Cancer (AJCC) th edition staging
Patients with American Joint Committee on Cancer (AJCC) (th edition, ) T-T nodal stage N or N or a T or T primary tumor with any nodal stage
Clinical American Joint Committee on Cancer (AJCC) stage II-III (AJCC, th ed.) with plans to be treated with concurrent chemoradiotherapy\r\n* Recurrent non-small cell lung cancer is allowed, provided the intent of the current treatment is curative and there has been no prior radiation to the thorax\r\n* Prior chemotherapy, immunotherapy, or targeted therapy is permitted as long as patients have recovered from prior toxicities to grade =< 
American Joint Committee on Cancer (AJCC) (th edition) stage IIb, III, or IV patients planned for resection of the primary tumor \r\n* >  cm in greatest dimension\r\n* Intermediate or high-grade \r\n* Superficial or deep
COHORT A: History or presence of regional pelvic lymph nodes (as per American Joint Committee on Cancer [AJCC] Cancer Staging [th edition]) will be considered a metastatic site if greater than . cm in shortest dimension
Any clinical T tumor as defined by tumor-node-metastasis classification in UICC/AJCC th edition, including inflammatory breast cancer
Clinical stage T-, N-c (American Joint Committee on Cancer [AJCC], seventh [th] edition [ed.]) without evidence of distant metastasis based on fludeoxyglucose (FDG) PET/CT\r\n* Patients who have squamous cell carcinoma of the neck of unknown primary, and thus, are T, are allowed with excision biopsy of a lymph node (or core biopsy) and consent from the principal investigator (PI) or coorperative (co)-PIs (Dr. Nancy Lee, Dr. Eric Sherman, or Dr. Nadeem Riaz)
With histologically or cytologically confirmed recurrent or refractory unresectable Stage IV gastric or gastro-esophageal junctional adenocarcinoma (according to American Joint Committee on Cancer/Union Internationale Contre le Cancer [UICC] th edition) and whose disease progressed after one or two prior chemotherapy regimen(s) involving both fluoropyrimidines and platinum
PART A: Patients must have histologically confirmed locally advanced (after failure of local therapy) or metastatic lung cancer (any histology, except carcinoid) stage IIIa, IIIb or IV (according to the th edition of the American Joint Committee on Cancer [AJCC] staging manual)
PART B: Patients must have histologically confirmed locally advanced (after failure of local therapy) or metastatic lung cancer (any histology, except carcinoid) stage IIIa, IIIb or IV (according to the th edition of the AJCC staging manual)
Stage IV disease by AJCC criteria (th edition).
Stage II or III disease by the American Joint Committee on Cancer (AJCC) th edition
STEP  ENROLLMENT: the patient has a diagnosis of American Joint Committee on Cancer (AJCC) th Edition stage IV NSCLC
STEP  ENROLLMENT AND RANDOMIZATION: the patient has a diagnosis of American Joint Committee on Cancer (AJCC) th edition stage IV NSCLC
Biopsy-proven invasive adenocarcinoma of the rectum, stage T- and/or node-positive (American Joint Committee on Cancer [AJCC] stage II or III) per AJCC staging manual, th edition; patients with Ma rectal cancer (metastasis confined to one organ or site [e.g., liver, lung, ovary, non regional node]\), stage IVA disease per the AJCC staging manual, th edition, are also eligible; for the purpose of this study, a tumor is located in the rectum when its distal edge is located =< cm from the anal verge; the distal edge of the tumor can be delineated by digital examination or endoscopic examination, including colonoscopy, although rigid proctoscopy is preferred
Histological diagnosis:\r\n* Histologically proven diagnosis of testicular seminoma\r\n** Histologically confirmed seminomatous germ cell tumor of the testis categorized as either \classical\ or \anaplastic\r\n* Stage I disease\r\n** Any pT N M S- (American Joint Committee on Cancer [AJCC], th Ed.)\r\n* Stage IIA or IIB disease\r\n** Any pT N M S- (AJCC, th Ed.)\r\n** Any pT N M S- (AJCC, th Ed.)\r\n** (At the discretion of the principal investigators, bulky stage IIB may be excluded from the study, according to National Comprehensive Cancer Center Guidelines)
Stage IV disease according to the th Edition of the American Joint Committee on Cancer staging system
Histologically or cytologically confirmed soft-tissue sarcoma, excluding alveolar and embryonal rhabdomyosarcoma, well- and dedifferentiated adipocytic sarcomas, Ewings, osteosarcoma, or gastrointestinal stromal tumor; American Joint Committee on Cancer (AJCC) (th Edition) Stage III or Ta Stage II or Stage IV treatment naive patients planned for resection of the primary tumor, with resectable metastatic disease
Patients with American Joint Committee on Cancer (th edition, ) stage IV cancer with distant metastases
Patients with American Joint Committee on Cancer (AJCC) seventh edition stage  metastatic non-small cell lung carcinoma
The patient must have clinical stage T-, N-, M-, stage II-IVC carcinoma as per the th edition of the American Joint Committee on Cancer (AJCC) staging manual; patients with TNM will be ineligible; patients with metastatic disease with a limited metastatic burden are eligible if obtaining local control is determined by their treating oncologist to be an important therapeutic goal
Patients with FDG-avid and pathologically proven stage IIA-IIB or IIIA-IIIB non-small cell lung cancer (according to American Joint Committee on Cancer [AJCC] staging, th edition)
Patients with cytologically or histologically confirmed non-small cell lung cancer (NSCLC)  locally advanced, stage IIIB OR stage IV or stage IVMA (malignant pleural or pericardial effusion or pleural implants) OR recurrence after primary surgery or radiotherapy (refer to  American Joint Committee on Cancer [AJCC] staging, th edition [Ed])
Resected, histologically proven, cutaneous melanoma determined to be Stage IIb, IIc, or III; according to the American Joint Commission of Cancer Staging, th edition
All patients must be either Stage IIIb/c or Stage IV according to the American Joint Committee on Cancer (AJCC) (th edition) and have histologically-confirmed melanoma that is felt to be surgically unresectable in order to be eligible. Please refer to the AJCC Cancer Staging Manual, th edition for a description of tumor, lymph node, metastasis and staging.
Subjects with a confirmed or suspected diagnosis of stage IA to stage IIIA non-small cell lung cancer scheduled for a lobectomy (Lung Cancer Staging per American Joint Committee on Cancer,th Edition);
Histologically or cytologically confirmed and documented stage IIIb/IV non-squamous NSCLC according to the American Joint Committee on Cancer Staging Manual (th Edition)
Histologically or cytologically proven adenocarcinoma of the breast stages II-III, according to the American Joint Committee on Cancer (AJCC) Staging Manual, th Edition, 
Patient who have AJCC th edition Prognostic Stage Group II
Histologically or cytologically confirmed adenocarcinoma of the rectum that was clinically staged T, T or node-positive (defined as >= N per American Joint Committee on Cancer [AJCC] th edition) that was treated with the following treatment with curative intent:\r\n* Curative surgical resection\r\n* Pre- or post-operative chemoradiation; and at least  months of combined adjuvant OR neoadjuvant systemic chemotherapy (equivalent to  cycles of leucovorin calcium, fluorouracil, and oxaliplatin [FOLFOX] or infusional fluorouracil [FU])
Patients must have histologically or cytologically confirmed stage I-III breast cancer (as defined by the revised, American Joint Committee on Cancer [AJCC] th edition criteria) and be at sufficient risk for tumor recurrence; staging studies to exclude metastatic disease are not required in asymptomatic patients; however, patients with findings considered suspicious for metastatic disease on any staging studies that are obtained need to be evaluated to exclude stage IV breast cancer
Diagnosis of RCC that is defined as metastatic by standard criteria (American Joint Committee on Cancer [AJCC] th edition, )
Histologically confirmed stage IV gastrointestinal (GI) cancer (American Joint Committee on Cancer [AJCC] th edition) currently sensitive to oxaliplatin containing chemotherapy regimen
Patients with American Joint Committee on Cancer (AJCC) th edition clinical stage IIB-IIIC
Patient must have proven or suspected non small cell lung cancer (NSCLC) and be clinical stage I or IIa, according to the th edition staging system of the American Joint Commission on Cancer for lung cancer (T or Ta, N or N, M)
Subjects with AJCC th edition stage TxN and M disease
Subjects with AJCC th edition stage TxN, Tb, and M disease
Patients must have pathologically confirmed diagnosis of unilateral ductal carcinoma in situ with no evidence of microinvasive or invasive disease obtained by core needle biopsy within  months of registration; if the core biopsy describes suspicion of microinvasion, patients remain eligible; patients diagnosed by surgical excision are not eligible; patients with synchronous bilateral disease (i.e.,\r\nsynchronous DCIS or invasive cancer) are not eligible\r\n* Patients will be staged prior to registration according to the clinical staging criteria adapted from the American Joint Committee on Cancer (AJCC) Cancer Staging Data Forms of the AJCC Cancer Staging Manual, th Edition, ; Note: for consistency purposes, AJCC th Edition will continue to be used throughout the entire study enrollment period
Patients must have stage I or II disease based on the parameters for staging NSCLC found in the American Joint Committee on Cancer (AJCC) cancer staging handbook, seventh (th) edition
Patient must have stage IIIA non-small cell lung cancer (T-N) per American Joint Committee on Cancer (AJCC) th edition and must be considered to be surgically resectable
Eligible patients must have appropriate staging studies identifying them as specific subsets of American Joint Committee on Cancer (AJCC) th edition stage I or II based on only one of the following combinations of tumor, nodes, metastatic (TNM) staging:\r\n* Ta-b, N, M\r\n* Ta, N, M\r\n* T (invading the chest wall, <  cm in diameter) N M
Patient must have clinical American Joint Committee on Cancer, th edition stage II or III breast cancer and be considered a candidate for curative mastectomy
American Joint Committee on Cancer (AJCC) th edition (ed.) stage cN or cN subsequently staged after surgery as stage pIB (Nmic), pIIA, pIIB, pIIIA, pIIIB, or Na ( or more axillary nodes) only: note that ypN will also be eligible if pathologic confirmation of nodal involvement was documented prior to neoadjuvant chemotherapy and the patient was found to be node negative at the time of surgery; note that women less than  years of age, women who received chemotherapy, patients staged as pN (i+ or mol+), and large-breasted women are eligible for enrollment